

Vitamin D insufficiency in the first 6 months of infancy and subsequent challenge-proven IgE-mediated food allergy: a case-cohort study.

John Molloy, MB Bao Bch, MRCPI,^{1,2,3,4}, Jennifer J. Koplin, PhD,^{3,4,5}; Katrina J. Allen, MBBS, BMedSc, FRACP, PhD,^{3,4,6,7}; Mimi L.K. Tang, MBBS, FRACP, FRCPA, PhD,^{3,4,6,7}; Fiona Collier, PhD,^{1,2,3}; John B. Carlin, PhD,^{3,5,6}; Richard Saffery, PhD,³; David Burgner, MB ChB, FRACP, PhD,^{3,6,8}; Sarath Ranganathan, MB ChB, MRCP, FRCPC, FRACP, PhD,^{3,6,9}; Terence Dwyer, PhD,¹⁰; Alister C. Ward, PhD,¹; Margarita Moreno-Betancur, PhD,^{3,11}; Michael Clarke, PhD,¹²; *Anne Louise Ponsonby, MBBS, PhD,^{3,4}; *Peter Vuillermine, MBBS, FRACP, PhD,^{1,2,3,4}, on behalf of the BIS investigator group

AFFILIATIONS:

¹*Deakin University, School of Medicine, Waurn Ponds, Australia*

²*Child Health Research Unit, Barwon Health, Geelong, Australia,*

³*Murdoch Childrens Research Institute, Parkville, Australia,*

⁴*Centre for Food and Allergy Research, Parkville, Australia,*

⁵*The University of Melbourne, Centre for Epidemiology and Biostatistics, Carlton, Australia.*

⁶*Department of Paediatrics, University of Melbourne, Parkville, Australia*

⁷*Department of Allergy and Immunology, Royal Children's Hospital, Parkville, Australia,*

⁸*Department of Paediatrics, Monash University, Clayton, Australia.*

⁹*Department of Respiratory Medicine, Royal Children's Hospital, Parkville, Australia,*

¹⁰*The George Institute for Global Health, University of Oxford, United Kingdom*

¹¹*Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia*

¹²*Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Western Australia.*

*Denotes equal contribution

CORRESPONDING AUTHOR:

Assoc/Prof. Peter Vuillermin,

Child Health Research Unit,

Kitchener House,

Ryrie Street,

Geelong,

Victoria, 3220,

Australia.

Email: peter.vuillermin@deakin.edu.au

Telephone: +61342153384

Funding

The establishment work and infrastructure for the BIS was provided by the Murdoch Childrens Research Institute, Deakin University and Barwon Health. Subsequent funding was secured from the National Health and Medical Research Council of Australia, The Jack Brockhoff Foundation, the Scobie Trust, the Shane O'Brien Memorial Asthma Foundation, the Our Women's Our Children's Fund Raising Committee Barwon Health, The Shepherd Foundation, the Rotary Club of Geelong, the Ilhan Food Allergy Foundation and GMHBA. Support in kind has been provided by The Cotton On Foundation and CreativeForce.

Abstract

Background

Ecological evidence suggests vitamin D insufficiency (VDI) due to lower ambient ultraviolet radiation (UVR) exposure may be a risk factor for IgE-mediated food allergy. However there are no studies relating directly measured VDI during early infancy to subsequent challenge-proven food allergy.

Objective

To prospectively investigate the association between VDI during infancy and subsequent challenge-proven food allergy.

Methods

In a birth cohort (n=1074), we used a case-cohort design to compare 25-hydroxy-vitamin-D₃ (25(OH)D₃) levels among infants with food allergy versus a random subcohort (n=274). The primary exposures were VDI (25(OH)D₃<50 nmol/L) at birth and 6 months of age. Ambient UVR and time in the sun were combined to estimate UVR exposure dose. IgE-mediated food allergy status at 1 year of age was determined by formal challenge. Binomial regression was used to examine associations between VDI, UVR exposure dose and food allergy, and investigate potential confounding.

Results

Within the random subcohort VDI was present in 45% (105/233) of newborns and 24% (55/227) of infants at 6 months. Food allergy prevalence at 1 year was 7.7% (61/786); 6.5% (53/808) were egg allergic and 1.5% (12/812) were peanut allergic. There was no evidence of an association between VDI at either birth (aRR 1.25, 95% CI 0.70-2.22) or 6 months (aRR 0.93, 95% CI 0.41-2.14) and subsequent food allergy.

Conclusions

There was no evidence that VDI during the first 6 months of infancy is a risk factor for subsequent food allergy. These findings primarily relate to egg allergy and larger studies are required.

Key words: cohort; eczema; food allergy; paediatrics; vitamin D;

Abbreviations:

UVR: Ultraviolet Radiation

VDI: vitamin D insufficiency

25(OH)D₃: 25-hydroxy-vitamin-D₃

25(OH)D: 25-hydroxy-vitamin-D

BIS: Barwon Infant Study

C3-epi-25(OH)D₃: C3-epimeric-25-hydroxyvitamin D₃

2D LC-MS/MS: two-dimensional ultra-performance liquid chromatography separation coupled tandem mass spectrometry

SCORAD: Scoring Atopic Dermatitis Scale

RR: Risk Ratio

aRR: adjusted Risk Ratio

Introduction

A concordant increase in allergic disease prevalence (1-6) and decrease in vitamin D status (7) has been reported in both developed and developing countries. This correlation has led to the hypothesis that low vitamin D status may influence the development of allergic disease including food allergy and eczema (8). Consistent with this, observational studies have found associations between proxy markers of ultraviolet radiation (UVR) exposure, the major source of vitamin D (9), and allergic disease. Latitudes further from the equator appear to be associated with higher rates of food allergy and eczema (10-12); and less consistently, autumn and winter births (periods of low UVR exposure (13)) may be more common among infants and children with food allergy (14-16). There is a substantial literature describing the biological mechanisms by which vitamin D may influence the risk of developing allergic disease (8) including effects on regulatory T cells (17) and bowel epithelial integrity (18). Moreover, ambient UVR has also been shown to affect immune modulation via non-vitamin D pathways (19) and may independently protect against allergic disease development (20).

A previous study reported a cross-sectional association between vitamin D₃ insufficiency (VDI; 25(OH)D₃ <50 nmol/L) and challenge-proven IgE-mediated food allergy among one-year-old infants of Australian-born parents, with evidence of a dose-response relationship (21). However the findings from prospective studies regarding directly measured maternal and infant vitamin D (25(OH)D) (22-26) or 25(OH)D₃ (27, 28) and subsequent allergic outcomes are conflicting, and limited by incomplete measurement of potential confounding factors and suboptimal case definition (22-28). Further, there has been minimal investigation of the potential role of UVR exposure in reducing risk of allergic disease independent of 25(OH)D pathways (29); and the hypothesis that the association between VDI and food allergy may be modified by microbial exposure has not been adequately tested (8).

The primary objective of this study was to utilise a population-derived birth cohort with detailed measurement of relevant covariates to prospectively evaluate the relationship between VDI during the first 6 months of infancy and subsequent challenge-proven IgE-mediated food allergy. In addition, we evaluated the relationship between UVR exposure and food allergy; as well as the relationship between VDI, UVR exposure and eczema.

Methods

Study design

The aims and methodology for the Barwon Infant Study (BIS) have been described previously (30). Briefly, a birth cohort of 1074 mother-infant pairs was assembled in the southeast of Australia using an unselected antenatal sampling frame. The Barwon region population characteristics are similar to those of the Australian population overall, but with a smaller proportion of families from non-English-speaking backgrounds (30). Mother-infant pairs were reviewed at regular intervals during pregnancy and the first year of life. Eczema symptoms and signs were recorded at each review and challenge-proven food allergy status was determined at 1 year. Among the infants who completed the 1 year review, 31% (274/894) were randomly selected to comprise the 'random subcohort'. 25(OH)D₃ was measured among infants in this subcohort as well as in those who had a positive food skin prick test (SPT) and/or had clinically proven food allergy. To minimise selection bias, analysis of the distribution and determinants of 25(OH)D₃, and analysis of the association between 25(OH)D₃ and eczema, was restricted to infants within the random subcohort. Relationships between UVR exposure dose and food allergy or eczema were investigated in the full BIS cohort.

Exposure measures

Vitamin D status

Blood samples were collected at four time points: maternal at 28-32 weeks gestation, infant at birth (cord blood), 6 months and 1 year (mean 13.03 months \pm S.D. 0.83). The 25(OH)D₃ metabolites (serum or plasma) and epimeric form, C3-epi-25-hydroxyvitamin D₃ (C3-epi-25(OH)D₃) were measured using two-dimensional ultra-performance liquid chromatography separation coupled tandem mass spectrometry detection (2D LC-MS/MS) (31). VDI was defined as 25(OH)D₃ <50 nmol/L and vitamin D deficiency as 25(OH)D₃ <25 nmol/L, levels which are based predominantly on markers of bone health (32, 33). An appropriate definition of VDI in relation to immune health remains uncertain.

UVR exposure

Questionnaire data quantifying exposure to direct sunlight daily were recorded during trimesters 1 and 2 of pregnancy, and at 4 weeks, 6 months and 1 year. The ambient UVR was estimated using monthly averages of daily total ambient UVR in standard erythemal doses (34) for Melbourne from 2010 to 2014, provided by the Australian Radiation Protection and Nuclear Safety Agency. Total UVR exposure dose was calculated as the product of time in direct sun and the average of the daily ambient UVR exposure. A total cumulative postnatal UVR exposure dose over the first year of life was estimated by dividing UVR exposure at 4 weeks, six months and twelve months into tertiles and assigning each tertile a score (0=lowest, 1=moderate and 2=highest). These scores were then summed to generate a cumulative postnatal UVR exposure dose score (lowest=0, highest=6) (35). A categorical score was created describing the parental report of sunscreen use during infant sun exposure. The score was included in a secondary analysis to test for the modifying effect sunscreen may have on actual personal UVR exposure (35).

Outcome measures

Food allergy status

At the 1 year review, infants underwent a SPT to five foods: cow's milk, egg, peanut, cashew and sesame (ALK-Abelló, Madrid, Spain) with a positive (10 mg/ml histamine) and negative (saline) control. Quintip® lancets (Hollister-Stier Laboratories, Spokane, WA) were used to perform SPT's on infant's backs. In clinical practice food sensitisation at 1 year of age is defined as a SPT wheal size 3mm or greater than the negative control in the presence of a positive histamine control (36), however recent studies have used a definition of 2mm or greater than the negative control in infants (21). A food allergen SPT wheal size of at least 2 mm greater than the negative control in the presence of a positive histamine control was defined as food sensitised in this study. All participants with SPT wheals 1 mm or more greater than the negative control were offered an in-hospital open food challenge (4). Those regularly ingesting the sensitised food at the time of SPT were defined as sensitised tolerant without formal challenge (n=12). If, on clinical review, the participant had a clinical history and reaction consistent with a diagnosis of IgE-mediated food allergy within 2 months of the 1 year review and a positive SPT, they were defined as food allergic without proceeding to food challenge (n=3) (4). Open food challenges (including raw egg) were performed under clinical supervision using validated protocols from the HealthNuts study (4). A positive challenge comprised one or more of the following criteria occurring within 2 hours of ingesting a dose of challenge food (4) :

- three or more concurrent non-contact urticaria for five minutes or longer;
- vomiting or diarrhoea;
- angioedema;
- anaphylaxis (circulatory or respiratory compromise).

These criteria were also used to define an IgE-mediated reaction occurring during the subsequent week-long home-based introduction if they had not reacted during the clinic challenge (n=1) (4). A negative challenge was defined by the full ingestion of the highest dose of the challenge food with no reaction and completion of the subsequent home-based introduction without reaction. The refusal of the child to eat the challenge food or complete all doses in the challenge protocol was deemed an inconclusive challenge (n=5).

Eczema status

Data on eczema were collected by questionnaires administered at 1, 3, 6, 9 months and 1 year; and clinical assessments were conducted at 1 month, 6 months and 1 year. Eczema was defined according to the modified UK working party criteria (37, 38). All infants had to have a history of itchy skin plus at least three of the following: a history of dry skin, a family history of allergy, a history of skin rash affecting the flexures or outer surfaces of the limbs or affecting the head or cheeks, or visible dermatitis assessed during a study visit at either 1 month, 6 months or 1 year (39). The Scoring Atopic Dermatitis Scale (SCORAD) was used to quantify eczema severity (40, 41).

Statistical analysis

Our primary hypothesis was that VDI in the first 6 months of infancy would be associated with subsequent food allergy. Infants with an inconclusive hospital food challenge result or indeterminate food allergy status were excluded from the food allergy analysis (n=30). For the food allergy case-cohort analysis we applied inverse probability weighting where the probability of selection for non-cases in the random subcohort was estimated by the fraction of infants included in the subcohort from the total cohort reviewed at 12 months in the BIS study (274/894). The probability of selection for food allergy cases was 1 (42).

Categorical variables were summarised using proportions. A propensity weighting approach was used to adjust the eczema prevalence to account for loss to follow-up over the first year of the study and provide an estimated period prevalence for the whole cohort (43). T-tests were used to compare the mean 25(OH)D₃ levels between food allergic infants and the random subcohort, and between infants within the random subcohort with and without eczema (Supplemental Tables EI and EII). Binomial regression models were fitted to estimate risk ratios (RR) for associations between exposures (VDI and UVR exposure dose) and subsequent food allergy or eczema. A further analysis examined the associations between VDI and food sensitisation. 25(OH)D₃ was also divided into quintiles to assess potential non-linear associations and thresholds other than 50 nmol/L (Supplemental Figures E3 & E4).

Ethnicity, family history of allergy, number of siblings, formula feeding and pet ownership were selected *a priori* to be included as covariates in the model as they have each been related to both 25(OH)D₃ and allergic disease. Smoking, livestock ownership, socioeconomic status (SES), birth weight, gender, season of birth, egg avoidance and time of solid introduction in infancy, maternal and infant vitamin D supplementation, C3-epi-25(OH)D₃ (31) concentration and mode of delivery at birth were retained in the model if they made a greater than 10% change to the risk ratio point estimate.

The relationship between change in 25(OH)D₃ status over the first 6 months of life and food allergy was investigated by fitting a multivariable binomial regression model, using 25(OH)D₃ at birth as a baseline variable, and change in 25(OH)D₃ status from birth to 6 months of age as an explanatory variable (44). An interaction term was specified to investigate effect modification by pet ownership (8).

To adjust for seasonal variation in 25(OH)D₃ levels, we fitted a sinusoidal curve with a period of 12 months to 25(OH)D₃ data using linear regression, and added the residuals from this model to the population average 25(OH)D₃ levels (45). For the C3-epi-25(OH)D₃ sensitivity analysis, C3-epi-25(OH)D₃ and 25(OH)D₃ were summed as a new variable representing total vitamin D exposure for the binary regression.

Analyses were performed using Stata (version 14.1, College Station, Texas).

Ethics

The study was approved by Barwon Health Human Research and Ethics Committee (HREC 10/24). Parents or guardians provided written informed consent for this study.

Results

Study population

The majority of participants were full term, Caucasian infants with Australian born parents (Table 1). The majority of mothers took vitamin D supplements during pregnancy and up to one third of infants were exposed to formula feeding (Table 1).

Vitamin D levels within the random subcohort

Within the random subcohort vitamin D₃ levels were measured among 233 infants at birth and 227 infants at six months. (Supplemental Figure E1). Forty five percent (105/233) of infants had VDI at birth and 24% (55/227) at 6 months. More than 82% of mothers reported taking a supplement containing vitamin D during pregnancy and maternal VDI was uncommon (9%), (Table I and Figure 1). The average ratio of birth 25(OH)D₃ to maternal 25(OH)D₃ was 0.61. The mean change in 25(OH)D₃ status from birth to 6 months was +15.0 nmol/L \pm S.D. 34.0.

Determinants of vitamin D status

At each time point, ambient UVR 6 weeks prior to blood draw was associated with 25(OH)D₃ status (Supplemental Table EVI). VDI in the first 6 months of life was less common among infants who were formula fed and who had no siblings (Supplemental Table EVI).

Food allergy and eczema prevalence

Of the 1074 eligible infants in the inception cohort, 83.2% (894) completed the 1 year review. 91.6% (819/894) of these had a valid skin prick test; and 82% (92/114) infants with a skin prick reaction to a food at least 1 mm larger than the negative control subsequently attended a formal in-hospital food challenge. A total of 58 had positive food challenges and 3 had previous clinical reactions meeting the criteria for clinically proven IgE-mediated food allergy. The prevalence of challenge-proven food allergy among infants completing the 1 year review with valid outcome measures was 7.7% (95% CI, 6.0-9.8), with egg allergy the most common, 6.5% (95% CI, 5.0-8.4) (Table II).

Eczema point prevalence rates in the cohort were: 0% at 1 month; 1.2% (12/973) at 3 months; 8.5% (78/923) at 6 months; 13.6% (120/880) at 9 months; and 8% (71/884) at 1 year. The estimated period prevalence of eczema during the first year of life for the whole cohort was 24.2% (95% CI 21.2%-27.3%). The average SCORAD in infants with eczema at 6 months was 9.9 (S.D. 11.4) with 69% (54/78) having a score consistent with mild disease (41) At 1 year the average SCORAD was 6.6 (S.D. 8.4) with 86% (61/71) having a score consistent with mild disease.

Vitamin D status and IgE-mediated food allergy

There was no evidence of an association between VDI at either birth (aRR 1.25, 95% CI 0.70-2.22) or 6 months (aRR 0.93, 95% CI 0.41-2.14) and subsequent food allergy, (Figure 2). Analyses using deseasonalised 25(OH)D₃ (Supplemental Figure E2 & Table EI) showed similar patterns of associations to the primary analysis. The mean 25(OH)D₃ level was similar at birth (Mean Difference 2.10 nmol/L, 95%CI -3.70-7.91) and 6 months (Mean Difference -2.16 nmol/L, 95%CI -10.2-5.9) among infants with and without subsequent food allergy (Supplemental Table EI). There was no evidence of an association between 25(OH)D₃ < 25 nmol/L at birth and subsequent food allergy (p=0.94). At each timepoint, there was some non-linearity between 25(OH)D₃ levels and food allergy risk (Supplemental Figures E3 & E4) but there was no evidence to support the use of a threshold other than 50 nmol/L.

There was no evidence that change in 25(OH)D₃ status from birth to 6 months of age was associated with subsequent food allergy (aRR 0.99, 95%CI 0.96-1.02). Adjusting for C3-epi-25(OH)D₃ in maternal samples, at birth or 6 months by adding to the 25(OH)D₃ level did not change the lack of association between 25(OH)D₃ and food allergy (Supplemental Table EIII).

There was no evidence that the lack of association between VDI during the first 6 months of infancy and food allergy was modified by pet ownership status as a marker of microbial experience (p=0.96).

There was also no association evident between maternal VDI and offspring food allergy (aRR 0.45 95%CI 0.06-3.47) (Supplemental Table EI), and only a weak indication of a cross-sectional association between VDI at food allergy at 1 year (aRR, 1.89 95%CI 0.86-4.13) (Figure 2).

Vitamin D status and eczema

Within the random subcohort there was no evidence of an association between VDI at either birth (aRR 0.88, 95%CI 0.54-1.43) or 6 months (aRR 0.84, 95%CI 0.33-2.14) and subsequent eczema (Figure 3). Adjustment for potential confounders made <10% difference to the estimated risk ratios. Analysis using deseasonalised 25(OH)D₃ also indicated no association between VDI and eczema (Supplemental Table EII & Figure E5).

Ambient UVR exposure dose and IgE-mediated food allergy

In the full cohort analysis there was no evidence of a prospective association between UVR exposure dose at individual time points, and subsequent food allergy at 1 year (Figure 4 & Supplemental Table EIV). Similarly, there was no evidence of a prospective association between maternal or infant UVR exposure dose and eczema in the first year of life (Supplemental Figure E6 & Table EV). There was no evidence that the relationship between UVR exposure and food allergy was modified by any level of sunscreen use (p=0.32 for moderate UVR exposure, p=0.92 for high UVR exposure).

Vitamin D status and food sensitisation

Food sensitisation at year 1 defined as a SPT wheal size 3mm or greater than the negative control: There was no evidence that VDI at any time point was associated with food sensitisation (Supplemental Table EVII). *Food sensitisation at year 1 defined as a SPT wheal size 2mm or greater than the negative control:* There was no evidence of an association between VDI during pregnancy or at birth and food sensitisation. There was however weak evidence of associations between VDI at six ($p=0.04$) and twelve months ($p=0.04$) and food sensitisation defined using this more inclusive threshold ($\geq 2\text{mm}$) (Supplemental Table EVIII).

Discussion

This is the first study to investigate 25(OH)D₃ measured during the first 6 months of infancy in relation to subsequent challenge-proven food allergy. In a predominantly Caucasian cohort, among whom raw egg was the most common food allergy, there was no evidence of an association between infant VDI during the first 6 months of infancy and subsequent IgE-mediated food allergy or eczema. There was also no evidence of an association between estimated UVR exposure dose and either food allergy or eczema.

VDI was present in almost half of the infants at birth and a quarter of infants at 6 months of age. Egg avoidance, the absence of formula feeding and a greater number of siblings were each associated with increased risk of VDI during infancy. However, a large proportion of the variation in vitamin D status remained unexplained and unmeasured genetic factors are likely to be important (35). Food allergy prevalence, whilst less common than observed in the Australian HealthNuts study (4), was still substantially higher than recent reports from Europe with similar outcomes (46, 47).

Over the last decade there has been intense interest in the potential relationship between VDI and food allergy, given a range of ecological findings and a wealth of mechanistic studies regarding the influence of 25(OH)D₃ on gut epithelial integrity (18, 48, 49) and immune function (17). However the data from studies relating directly measured 25(OH)D or 25(OH)D₃ during early infancy to various markers of allergic disease are conflicting. Early papers reported positive associations between low cord blood 25(OH)D and subsequent allergic sensitisation (50, 51) and eczema (52). Another study using cord blood 25(OH)D₃ also reported similar associations with eczema (27). More recent studies have been unable to replicate these positive associations using either 25(OH)D (22, 53) or 25(OH)D₃ (28) as the exposure. The current paper extends the body of evidence against a prospective association between VDI and allergy by measuring 25(OH)D₃ at two time-points during early infancy and including the more robust and clinically relevant measure of challenge-proven food allergy status.

Birth 25(OH)D₃ was generally around sixty percent of the maternal level, consistent with previous studies (54). Thus relatively lower 25(OH)D₃ levels in cord blood may be physiological, and it is uncertain whether a cut-off of 50 nmol/L to define VDI in cord blood is appropriate, particularly as this threshold is based predominantly on markers of bone health

in adults (32) and an appropriate immune related level remains uncertain. Accordingly, we explored a range of threshold levels including $25(\text{OH})\text{D}_3 < 25 \text{ nmol/L}$ as well as $25(\text{OH})\text{D}_3$ quintiles, but remained unable to identify a relationship between cord $25(\text{OH})\text{D}_3$ and subsequent food allergy.

It has been proposed that $25(\text{OH})\text{D}_3$ status may be particularly important during the period of introduction of dietary solids (8, 55). A small study has previously suggested $25(\text{OH})\text{D}_3$ may promote immune tolerance during initial exposure to solids (56), but our study is the first to relate $25(\text{OH})\text{D}_3$ around the time of weaning to the clinically relevant outcome of challenge-proven food allergy. There was no evidence of an association between VDI at 6 months and subsequent food allergy.

Whilst there is consistent evidence of an association between latitudes further from the equator and various proxy markers of food allergy prevalence (10, 11, 14, 57), we were unable to demonstrate an association between UVR exposure measured at the individual level and allergic outcomes. Our measure, which combined ambient UVR and parent-reported time in the sun (35) was associated with $25(\text{OH})\text{D}_3$ at each time point, and is likely to provide a more accurate estimate than latitude alone, which may be a proxy for a wide range of factors including ethnicity, genetics and microbial environment. Our findings therefore suggest that the relationship between latitude and allergic disease may relate to factors other than $25(\text{OH})\text{D}_3$ status.

The strengths of the study include the use of a population-derived cohort with adequate retention rates; measurement of infant $25(\text{OH})\text{D}_3$ at both birth and during the introduction of solids; delineation of food allergy status by formal food challenge; and detailed measurement of relevant covariates, including UVR exposure at the individual level. We were also able to conduct relevant sensitivity analyses and tests of effect modification, and show that these did not substantially alter the findings. The predominantly Caucasian cohort limits the generalisability of the findings, and this may be important in the context of growing evidence that the relationship between either $25(\text{OH})\text{D}$ (58) or $25(\text{OH})\text{D}_3$ (45) and food allergy may be modified by genetic factors. On the other hand, the relative homogeneity of the BIS cohort assists internal validity. We did not measure free $25(\text{OH})\text{D}$ and vitamin D binding protein which limited our ability to investigate the role of bioavailable $25(\text{OH})\text{D}$. The statistical power was limited by the number of food allergy cases and it is important to recognise that the 95% confidence intervals around our point estimates did not exclude potential effects of a relative risk up to about 2-fold. It is also noteworthy that there were only 12 cases of peanut allergy; and the aRR regarding a cross-sectional association between VDI and food allergy at 1 year is not inconsistent with the positive association observed among infants of Australian parents in the HealthNuts study (21). We were unable to conduct a meaningful analysis of the relationship between $25(\text{OH})\text{D}_3$ status and severe eczema as there were very few children with severe eczema in the current study.

In conclusion, in a predominantly Caucasian cohort, in which egg was the commonest food allergy, there was no evidence of a longitudinal association between either VDI during the first 6 months of infancy, or UVR exposure, and subsequent challenge-proven food allergy or eczema. Our findings require replication in larger observational studies and/or clinical trials, including a sufficient number of children with peanut allergy, and relating directly measured $25(\text{OH})\text{D}_3$ to robust measures of clinically relevant food allergy status. Until such studies are completed, the balance of current evidence does not support the widespread implementation

of routine vitamin D supplementation during early infancy for the purpose of preventing allergic outcomes.

Acknowledgements

We thank the BIS participants for the generous contribution they have made to this project. We also thank current and past staff for their efforts in recruiting and maintaining the cohort and in obtaining and processing the data and biospecimens.

References

1. Liew WK, Chiang WC, Goh AE, Lim HH, Chay OM, Chang S, et al. Paediatric anaphylaxis in a Singaporean children cohort: changing food allergy triggers over time. *Asia Pac Allergy* 2013;**3**(1):29-34.
2. Gupta RS, Springston EE, Smith B, Warrier MR, Pongracic J, Holl JL. Geographic variability of childhood food allergy in the United States. *Clin Pediatr (Phila)* 2012;**51**(9):856-861.
3. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. *Thorax* 2007;**62**(1):91-96.
4. Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol* 2011;**127**(3):668-676.e661-662.
5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. *J Allergy Clin Immunol* 2009;**124**(6):1251-1258 e1223.
6. Martin PE, Koplin JJ, Eckert JK, Lowe AJ, Ponsonby AL, Osborne NJ, et al. The prevalence and socio-demographic risk factors of clinical eczema in infancy: a population-based observational study. *Clin Exp Allergy* 2013;**43**(6):642-651.
7. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**(3):266-281.
8. Vassallo MF, Camargo CA, Jr. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. *J Allergy Clin Immunol* 2010;**126**(2):217-222.
9. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr* 2005;**135**(2):317-322.
10. Camargo CA, Jr., Clark S, Kaplan MS, Lieberman P, Wood RA. Regional differences in EpiPen prescriptions in the United States: the potential role of vitamin D. *J Allergy Clin Immunol* 2007;**120**(1):131-136.
11. Mullins RJ, Clark S, Camargo CA. Regional variation in epinephrine autoinjector prescriptions in Australia: more evidence for the vitamin D-anaphylaxis hypothesis. *Ann Allergy Asthma Immunol* 2009;**103**(6):488-495.
12. Osborne NJ, Ukoumunne OC, Wake M, Allen KJ. Prevalence of eczema and food allergy is associated with latitude in Australia. *J Allergy Clin Immunol* 2012;**129**(3):865-867.

13. Samanek AJ, Croager EJ, Gies P, Milne E, Prince R, McMichael AJ, et al. Estimates of beneficial and harmful sun exposure times during the year for major Australian population centres. *Med J Aust* 2006;**184**(7):338-341.
14. Vassallo MF, Banerji A, Rudders SA, Clark S, Mullins RJ, Camargo CA, Jr. Season of birth and food allergy in children. *Ann Allergy Asthma Immunol* 2010;**104**(4):307-313.
15. Vassallo MF, Banerji A, Rudders SA, Clark S, Camargo CA, Jr. Season of birth and food-induced anaphylaxis in Boston. *Allergy* 2010;**65**(11):1492-1493.
16. Mullins RJ, Clark S, Katelaris C, Smith V, Solley G, Camargo CA, Jr. Season of birth and childhood food allergy in Australia. *Pediatr Allergy Immunol* 2011;**22**(6):583-589.
17. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J Clin Invest* 2006;**116**(1):146-155.
18. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol* 2008;**294**(1):G208-216.
19. Gorman S, Scott NM, Tan DH, Weeden CE, Tuckey RC, Bisley JL, et al. Acute erythematultraviolet radiation causes systemic immunosuppression in the absence of increased 25-hydroxyvitamin D3 levels in male mice. *PLoS One* 2012;**7**(9):e46006.
20. Rudders SA, Camargo CA, Jr. Sunlight, vitamin D and food allergy. *Curr Opin Allergy Clin Immunol* 2015;**15**(4):350-357.
21. Allen KJ, Koplin JJ, Ponsonby AL, Gurrin LC, Wake M, Vuillermin P, et al. Vitamin D insufficiency is associated with challenge-proven food allergy in infants. *J Allergy Clin Immunol* 2013;**131**(4):1109-1116, 1116 e1101-1106.
22. Wegienka G, Havstad S, Zoratti EM, Kim H, Ownby DR, Johnson CC. Association between vitamin D levels and allergy-related outcomes vary by race and other factors. *J Allergy Clin Immunol* 2015;**136**(5):1309-1314 e1301-1304.
23. Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, et al. Maternal vitamin D status during pregnancy and child outcomes. *Eur J Clin Nutr* 2008;**62**(1):68-77.
24. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, Workman L, Sordillo JE, Camargo CA, Jr., et al. Prenatal, perinatal, and childhood vitamin D exposure and their association with childhood allergic rhinitis and allergic sensitization. *J Allergy Clin Immunol* 2016;**137**(4):1063-1070 e1061-1062.
25. Chawes BL, Bonnelykke K, Jensen PF, Schoos AM, Heickendorff L, Bisgaard H. Cord blood 25(OH)-vitamin D deficiency and childhood asthma, allergy and eczema: the COPSAC2000 birth cohort study. *PLoS One* 2014;**9**(6):e99856.
26. Mullins RJ, Clark S, Wiley V, Eyles D, Camargo CA, Jr. Neonatal vitamin D status and childhood peanut allergy: a pilot study. *Ann Allergy Asthma Immunol* 2012;**109**(5):324-328.
27. Jones AP, Palmer D, Zhang G, Prescott SL. Cord blood 25-hydroxyvitamin D3 and allergic disease during infancy. *Pediatrics* 2012;**130**(5):e1128-1135.
28. Weisse K, Winkler S, Hirche F, Herberth G, Hinz D, Bauer M, et al. Maternal and newborn vitamin D status and its impact on food allergy development in the German LINA cohort study. *Allergy* 2013;**68**(2):220-228.
29. Kemp AS, Ponsonby AL, Pezic A, Cochrane JA, Dwyer T, Jones G. The influence of sun exposure in childhood and adolescence on atopic disease at adolescence. *Pediatr Allergy Immunol* 2013;**24**(5):493-500.
30. Vuillermin P, Saffery R, Allen KJ, Carlin JB, Tang ML, Ranganathan S, et al. Cohort Profile: The Barwon Infant Study. *Int J Epidemiol* 2015;**44**(4):1148-1160.
31. Clarke M, Tuckey R, Gorman S, Holt B, Hart P. Optimized 25-hydroxyvitamin D analysis using liquid-liquid extraction with 2D separation with LC/MS/MS detection, provides superior precision compared to conventional assays. *Metabolomics* 2013;**9**(5):1031-1040.
32. Wagner CL, Greer FR, American Academy of Pediatrics Section on B, American Academy of Pediatrics Committee on N. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. *Pediatrics* 2008;**122**(5):1142-1152.
33. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC); 2011.

34. Diffey BL, Jansen CT, Urbach F, Wulf HC. The standard erythema dose: a new photobiological concept. *Photodermatol Photoimmunol Photomed* 1997;**13**(1-2):64-66.
35. Suaini NH, Koplin JJ, Ellis JA, Peters RL, Ponsonby AL, Dharmage SC, et al. Environmental and genetic determinants of vitamin D insufficiency in 12-month-old infants. *J Steroid Biochem Mol Biol* 2014;**144 Pt B**:445-454.
36. Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. *Pediatr Allergy Immunol* 2004;**15**(5):435-441.
37. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol* 1994;**131**(3):406-416.
38. Fleming S, Bodner C, Devereux G, Russell G, Campbell D, Godden D, et al. An application of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants. *J Invest Dermatol* 2001;**117**(6):1526-1530.
39. Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-Browne RM, et al. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. *Pediatr Allergy Immunol* 2012;**23**(7):674-681.
40. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology* 1993;**186**(1):23-31.
41. Pucci N, Novembre E, Cammarata MG, Bernardini R, Monaco MG, Calogero C, et al. Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. *Allergy* 2005;**60**(1):113-116.
42. Lumley T. *Complex Surveys: A Guide to Analysis Using R*. 1st ed. ed. Hoboken, New Jersey.: John Wiley & Sons.; 2010.
43. Rubin DB, Little RJ. *Statistical analysis with missing data*. Hoboken, NJ: J Wiley & Sons 2002.
44. De Stavola BL, Nitsch D, dos Santos Silva I, McCormack V, Hardy R, Mann V, et al. Statistical issues in life course epidemiology. *Am J Epidemiol* 2006;**163**(1):84-96.
45. Koplin JJ, Suaini NH, Vuillermin P, Ellis JA, Panjari M, Ponsonby AL, et al. Polymorphisms affecting vitamin D-binding protein modify the relationship between serum vitamin D (25[OH]D3) and food allergy. *J Allergy Clin Immunol* 2016;**137**(2):500-506 e504.
46. Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M, Kenny L, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. *J Allergy Clin Immunol* 2016;**137**(4):1111-1116 e1118.
47. Dogruel D, Bingol G, Altintas DU, Yilmaz M, Guneser Kendirli S. Clinical Features of Food Allergy during the 1st Year of Life: The ADAPAR Birth Cohort Study. *Int Arch Allergy Immunol* 2016;**169**(3):171-180.
48. Assa A, Vong L, Pinnell LJ, Avitzur N, Johnson-Henry KC, Sherman PM. Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation. *J Infect Dis* 2014;**210**(8):1296-1305.
49. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)₂ vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. *BMC Gastroenterol* 2012;**12**:57.
50. Rothers J, Wright AL, Stern DA, Halonen M, Camargo CA, Jr. Cord blood 25-hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson, Arizona. *The Journal of allergy and clinical immunology* 2011;**128**(5):1093-1099 e1091-1095.
51. Liu X, Arguelles L, Zhou Y, Wang G, Chen Q, Tsai HJ, et al. Longitudinal trajectory of vitamin D status from birth to early childhood in the development of food sensitization. *Pediatr Res* 2013;**74**(3):321-326.
52. Baiz N, Dargent-Molina P, Wark JD, Souberbielle JC, Annesi-Maesano I, Group EM-CCS. Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis. *J Allergy Clin Immunol* 2014;**133**(1):147-153.
53. Visness CM, Sandel MT, O'Connor G, Gern JE, Jaffee KF, Wood RA, et al. Cord blood vitamin D concentrations are unrelated to atopy and wheeze in 2 diverse birth cohort studies. *J Allergy Clin Immunol* 2015;**136**(4):1108-1110 e1102.

54. Roth DE. Vitamin D supplementation during pregnancy: safety considerations in the design and interpretation of clinical trials. *J Perinatol* 2011;**31**(7):449-459.
55. Molloy J, Ponsonby AL, Allen KJ, Tang ML, Collier FM, Ward AC, et al. Is Low Vitamin D Status A Risk Factor For Food Allergy? Current Evidence And Future Directions. *Mini Rev Med Chem* 2015;**15**(11):944-952.
56. Jones AP, D'Vaz N, Meldrum S, Palmer DJ, Zhang G, Prescott SL. 25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life. *Clin Exp Allergy* 2015;**45**(1):220-231.
57. Mullins RJ, Clark S, Camargo CA, Jr. Regional variation in infant hypoallergenic formula prescriptions in Australia. *Pediatr Allergy Immunol* 2010;**21**(2 Pt 2):e413-420.
58. Liu X, Wang G, Hong X, Wang D, Tsai HJ, Zhang S, et al. Gene-vitamin D interactions on food sensitization: a prospective birth cohort study. *Allergy* 2011;**66**(11):1442-1448.